Levosimendan Bioglan

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Bioglan (Levosimendan)

Q: What is Levosimendan Bioglan used for?

Levosimendan Bioglan is used primarily to treat acute decompensated heart failure in adult patients. It works as an inotropic agent to improve cardiac output and relieve symptoms associated with low‑output heart failure.

Q: How does Levosimendan work?

Levosimendan sensitises troponin C to calcium, enhancing myocardial contractility without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces both preload and afterload.

Q: What is the usual dose of Levosimendan Bioglan?

The dosage and infusion rate of Levosimendan Bioglan are determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber sets the appropriate regimen.

Q: Is Levosimendan safe during pregnancy or breastfeeding?

Safety data for Levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

Q: How do I order Levosimendan Bioglan from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Levosimendan compare with other inotropes?

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a dual mechanism not seen with many other agents.

Q: What are the storage and handling requirements for Levosimendan Bioglan?

Levosimendan Bioglan should be stored below 25 °C, protected from moisture and direct sunlight, and kept in its original packaging. Follow any additional handling instructions provided with the product to maintain stability.

Q: How is Levosimendan administered?

Levosimendan is administered intravenously, typically as a loading infusion followed by a continuous maintenance infusion. The exact infusion protocol is determined by the treating physician based on the patient’s condition.

Q: What are the most serious risks associated with Levosimendan?

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for these events during and after infusion.

Q: Who should not use Levosimendan Bioglan?

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension (systolic BP <90 mmHg), and individuals with certain uncontrolled cardiac arrhythmias. Clinicians must evaluate each patient’s medical history before prescribing.

Levosimendan, the active ingredient in Levosimendan Bioglan, is a calcium sensitizer presented as an intravenous solution for intravenous administration. It is indicated for the treatment of acute decompensated heart failure, improving cardiac output in adult patients with severe ventricular dysfunction.

GNH India supplies Levosimendan Bioglan as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres and specialty clinics worldwide under regulated quality standards. The company ensures batch‑to‑batch consistency, proper documentation, and compliance with EU marketing authorisation requirements.

Manufacturer / TM Owner

Bioglan Ab

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is a calcium sensitizer used in the management of heart failure.
Acute decompensated heart failure: improves cardiac output and reduces symptoms of low cardiac output in hospitalized patients.
Chronic heart failure (off‑label): may be considered to enhance hemodynamics when conventional therapy is insufficient.
Cardiogenic shock (off‑label): can provide inotropic support while avoiding increased intracellular calcium.

How It Works

Levosimendan increases myocardial contractility by binding to troponin C and sensitizing it to calcium, which enhances the force of contraction without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing both preload and afterload, thereby improving overall cardiac performance.

Side Effects

Levosimendan may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

Hypotension: reduction in blood pressure, especially after rapid infusion.
Headache: mild to moderate intensity during treatment.
Nausea: occasional gastrointestinal discomfort.
Tachycardia: increased heart rate observed in some patients.
Dizziness: feeling of light‑headedness, often related to blood pressure changes.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.
Liver enzyme elevation: abnormal hepatic function tests.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures before and during therapy.
Monitor blood pressure: watch for significant drops, especially during loading dose.
Monitor cardiac rhythm: observe for arrhythmias via continuous ECG.
Use cautiously in renal impairment: dose adjustment may be needed.
Avoid in severe hypotension: contraindicated if systolic pressure is <90 mmHg.
Discontinue if allergic reaction occurs: stop infusion and provide appropriate treatment.
Store below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Levosimendan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension.
Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.
Other calcium sensitizers: additive inotropic effect leading to arrhythmias.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may blunt desired inotropic response.
Diuretics: enhance volume depletion and hypotension risk.
ACE inhibitors/ARBs: synergistic blood pressure lowering.
Other inotropes (e.g., dobutamine): may require dose adjustments.
Anticoagulants: monitor for bleeding if hypotension occurs.

Frequently Asked Questions

Levosimendan Bioglan is used primarily to treat acute decompensated heart failure in adult patients. It works as an inotropic agent to improve cardiac output and relieve symptoms associated with low‑output heart failure.

Levosimendan sensitises troponin C to calcium, enhancing myocardial contractility without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces both preload and afterload.

The dosage and infusion rate of Levosimendan Bioglan are determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber sets the appropriate regimen.

Safety data for Levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a dual mechanism not seen with many other agents.

Levosimendan Bioglan should be stored below 25 °C, protected from moisture and direct sunlight, and kept in its original packaging. Follow any additional handling instructions provided with the product to maintain stability.

Levosimendan is administered intravenously, typically as a loading infusion followed by a continuous maintenance infusion. The exact infusion protocol is determined by the treating physician based on the patient’s condition.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for these events during and after infusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension (systolic BP <90 mmHg), and individuals with certain uncontrolled cardiac arrhythmias. Clinicians must evaluate each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.